All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
During ESH 3rd How to Diagnose and Treat Acute Leukaemias the ALL Hub spoke with Emily Curran, University of Cincinnati, Cincinnati, US. We asked, How effective is targeted therapy for Ph-like ALL?
How effective is targeted therapy for Ph-like ALL?
Curran begins by outlining the Ph-like ALL subtype and current trial approaches, focusing on targets such as the ABL or JAK- targetable pathways. She discusses the results of some of this data in terms of clinical and pre-clinical models. Finally Curran discusses future studies, e.g. effectivity in less common Ph-like subtypes and the incorporation of novel immunotherapies like blinatumomab and Inotuzumab .
How should we treat a patient who has a molecular relapse after transplant?
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Lori Muffly, Stanford University, Stanford, US. We asked, How should we...
The current treatment landscape of acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a rare hematological disorder with a bimodal incidence in childhood and in older adults. The advent of multiple chemotherapies has drastically...
Subscribe to get the best content related to ALL delivered to your inbox